Navigation Links
Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug
Date:2/18/2009

BEIJING, Feb. 18 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS, "Lotus" or the "Company"), a company that controls and operates pharmaceutical companies in the People's Republic of China ("PRC"), today announced that contractually controlled Beijing Liang Fang Pharmaceutical Co., Ltd. ("Liang Fang") entered into an intellectual rights transfer contract with Beijing Yipuan Bio-Medical Technology Co., Ltd. ("Yipuan") in December 2008 to acquire the drug Yipubishan, a highly effective and stable octreotide acetate injection solution, according to a clinical research report issued by Beijing Union Medical College Hospital Center for Clinical Pharmacology, used to treat the symptoms of gastric ulcers and hemorrhages of the upper digestive tract since 2004.

Liang Fang will pay RMB54 million (about $7.9 million) in installments within six months of the date of signing the intellectual rights transfer contract with Yipuan (the intellectual property rights to Yipubishan are documented in an official drug certificate for Yipubishan). Liang Fang has paid RMB20 million (approximately $2.9 million) to Yipuan as of December 31, 2008 and the remaining balance of RMB34 million (approximately $5 million) is due by May 31, 2009. Liang Fang intends to use its present working capital to fund the project.

Part of the development costs of Yipubishan were funded through the use of grants from the Innovation Fund for Small - Medium Technology Based Firms of the Ministry of Science and Technology of the PRC. Because of its advanced bio-medical technology and impact, Yipubishan became the first prescription drug of its kind developed in China to be included in the National Torch Project. The National Torch Project, approved by China State Department, recognizes and promotes commercialization of high-tech discoveries and encourages companies to use high technology.

Estimated thi
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
2. Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference
3. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
4. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
5. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
6. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
7. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
8. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
9. Lotus Pharmaceuticals Raises $5 Million in Private Placement
10. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
11. Lotus Blossom Consulting Announces E-Book on Infertility Treatment Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... 21, 2014 The Laboratory Testing Services ... manufacturers perform tests on items ranging from consumer and ... society, pressure on operators to ensure the safety and ... greater number of government safety regulations and consumer lawsuits ... to sale. Although revenue briefly dipped in 2009 as ...
(Date:9/21/2014)... York, NY (PRWEB) September 21, 2014 ... enabled more generic drugs to inundate the market, thereby ... Pharmaceutical Manufacturing industry. According to data from Industry ... has cost the industry $1.8 and $2.5 billion in ... brand-name drugs losing patent exclusivity, which has hampered revenue ...
(Date:9/21/2014)... 22, 2014 The asthma market ... as it has become saturated with relatively efficacious ... corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), ... increasing generic competition. However, the launch of seven ... ICS/LABA therapies delivered by the next-generation inhalers will ...
(Date:9/21/2014)... The Illinois Joining Forces Behavioral Health ... symposium ( tinyurl.com/ILBHC14 ) focused on improving care ... by the VNA Foundation, Thresholds, Illinois Department of ... & Disability Advocates, the symposium will be held ... Springfield, IL. The symposium features keynote speakers ...
(Date:9/21/2014)... September 21, 2014 Hundreds of ... forward in Pennsylvania’s Philadelphia Court of Common Pleas, ... the proceeding’s next monthly meeting has been scheduled ... 100300296) , “Our Firm is representing a number ... this litigation. We are pleased with its continued ...
Breaking Medicine News(10 mins):Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4
... say combining a 6 percent salicylic acid gel with ... for plaque psoriasis, an inflammatory skin condition characterized by ... study 30 adults with plaque-type psoriasis were observed for ... acid gel plus 0.1 percent tacrolimus ointment or 6 ...
... According to findings of a recent study researchers say ... kidney stone formation.//Researchers believe larger body size causes increased ... higher risk for calcium-containing kidney stones. ,The association ... gain, body mass index, and waist circumference was studied ...
... past have shown conflicting results over whether hormone replacement ... A recent study however examines the pros and cons ... used combined HRT therapy for five years. All the ... participants had menopausal symptoms, while others did not.Results showed ...
... intake during pregnancy may increase the likelihood of eczema ... according to a recent study.// ,2,000 women were ... the development of asthma and eczema in children. The ... women. The participants were required to fill out questionnaires ...
... results suggest people who carry a gene that produces ... a small increased risk for stroke.// ,Researchers reviewed ... was found that previous study results were observational in ... out confounding factors by looking at data on the ...
... Year has brought with it a new lease of life ... //patients the uphill struggle doesn’t stop with finding a matching ... Research has shown that despite all high tech matching done ... phenomenon. Transplant surgeon Ignazio Marino, M.D., of Thomas Jefferson University ...
Cached Medicine News:
(Date:9/19/2014)... Sept. 19, 2014 UBM Medica US announces ... online community to help oncologists and other clinicians gain ... the use of targeted therapies and immunotherapies, discusses some ... treatment.  Every September, Blood Cancer ... raise awareness about blood cancers—helping to increase survival rates ...
(Date:9/19/2014)... Sept. 19, 2014  Pressure BioSciences, Inc. (OTCQB: ... has received and approved all parts required to ... has begun to manufacture the new PCT-based instrument ... be ready for shipment by mid-October and that ... at a rate of about one per week ...
(Date:9/19/2014)...  Over 200 runners participated in the fifth annual ... Oncology Institute (ROI), hosted by Radiation Business Solutions. This year ... San Francisco.  "Donations are still coming ... Business Solutions, "but at this point, through registrations ... the ROI this year. This surpasses last year,s record ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
... Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced ... approval for Pixuvri™ (pixantrone dimaleate) for the treatment ... aggressive non-Hodgkin,s lymphoma ("NHL") was validated and accepted ... Validation indicates that the application is complete and ...
... 2010 Hanger Orthopedic Group, Inc. (NYSE: ... (the "Offer") for any and all of its outstanding 10 ... expired at 8:00 a.m., New York City time, on November 17, ... $172,443,000 aggregate principal amount of Notes had been validly tendered ...
Cached Medicine Technology:The European Medicines Agency Validates and Accepts Cell Therapeutics' Marketing Authorization Application for Pixuvri™ 2The European Medicines Agency Validates and Accepts Cell Therapeutics' Marketing Authorization Application for Pixuvri™ 3Hanger Orthopedic Group, Inc. Announces Expiration of Offer to Purchase Outstanding 10 1/4% Senior Notes Due 2014 2Hanger Orthopedic Group, Inc. Announces Expiration of Offer to Purchase Outstanding 10 1/4% Senior Notes Due 2014 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: